CS238645B2 - Design method of plasmide capable to separate heterological gen - Google Patents
Design method of plasmide capable to separate heterological gen Download PDFInfo
- Publication number
- CS238645B2 CS238645B2 CS816230A CS623083A CS238645B2 CS 238645 B2 CS238645 B2 CS 238645B2 CS 816230 A CS816230 A CS 816230A CS 623083 A CS623083 A CS 623083A CS 238645 B2 CS238645 B2 CS 238645B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- plasmid
- trp
- promoter
- gene
- fragment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 130
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 90
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 83
- 229920001184 polypeptide Polymers 0.000 claims abstract description 78
- 108020004414 DNA Proteins 0.000 claims abstract description 67
- 102000053602 DNA Human genes 0.000 claims abstract description 25
- 241000894006 Bacteria Species 0.000 claims abstract description 12
- 239000013612 plasmid Substances 0.000 claims description 148
- 239000012634 fragment Substances 0.000 claims description 103
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 53
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 53
- 239000004098 Tetracycline Substances 0.000 claims description 37
- 229960002180 tetracycline Drugs 0.000 claims description 37
- 229930101283 tetracycline Natural products 0.000 claims description 37
- 235000019364 tetracycline Nutrition 0.000 claims description 37
- 150000003522 tetracyclines Chemical class 0.000 claims description 37
- 229960000723 ampicillin Drugs 0.000 claims description 21
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 21
- 230000001580 bacterial effect Effects 0.000 claims description 15
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 108700026220 vif Genes Proteins 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 abstract description 20
- 125000003729 nucleotide group Chemical group 0.000 abstract description 20
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 7
- 108091033380 Coding strand Proteins 0.000 abstract description 6
- 230000014621 translational initiation Effects 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 42
- 102000004169 proteins and genes Human genes 0.000 description 42
- 238000003776 cleavage reaction Methods 0.000 description 35
- 230000007017 scission Effects 0.000 description 35
- 241000588724 Escherichia coli Species 0.000 description 34
- 239000000047 product Substances 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 102000037865 fusion proteins Human genes 0.000 description 23
- 108020001507 fusion proteins Proteins 0.000 description 23
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 22
- 230000028327 secretion Effects 0.000 description 22
- 108020004705 Codon Proteins 0.000 description 21
- 230000029087 digestion Effects 0.000 description 21
- 238000001962 electrophoresis Methods 0.000 description 21
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 21
- 108010000521 Human Growth Hormone Proteins 0.000 description 20
- 108091008146 restriction endonucleases Proteins 0.000 description 20
- 150000001413 amino acids Chemical group 0.000 description 17
- 108010056088 Somatostatin Proteins 0.000 description 15
- 239000006137 Luria-Bertani broth Substances 0.000 description 14
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 14
- 102000002265 Human Growth Hormone Human genes 0.000 description 13
- 239000000854 Human Growth Hormone Substances 0.000 description 13
- 102000005157 Somatostatin Human genes 0.000 description 13
- 229960000553 somatostatin Drugs 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 238000010276 construction Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 238000013519 translation Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000013615 primer Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 101100122010 Methanocella arvoryzae (strain DSM 22066 / NBRC 105507 / MRE50) glmM gene Proteins 0.000 description 7
- 108020004511 Recombinant DNA Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000003248 secreting effect Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 6
- 102000012410 DNA Ligases Human genes 0.000 description 6
- 108010061982 DNA Ligases Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 6
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 108060002716 Exonuclease Proteins 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 5
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 102000013165 exonuclease Human genes 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 108010046075 Thymosin Proteins 0.000 description 4
- 102000007501 Thymosin Human genes 0.000 description 4
- 238000012869 ethanol precipitation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 4
- -1 o-carbonylphenylamino Chemical group 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 239000008051 TBE buffer Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- WTFXTQVDAKGDEY-UHFFFAOYSA-N (-)-chorismic acid Natural products OC1C=CC(C(O)=O)=CC1OC(=C)C(O)=O WTFXTQVDAKGDEY-UHFFFAOYSA-N 0.000 description 2
- 0 *C(CC=C)C1CC(CCCC=N*C=*)C1 Chemical compound *C(CC=C)C1CC(CCCC=N*C=*)C1 0.000 description 2
- LXCUAFVVTHZALS-UHFFFAOYSA-N 3-(3-methoxyphenyl)piperidine Chemical compound COC1=CC=CC(C2CNCCC2)=C1 LXCUAFVVTHZALS-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- WTFXTQVDAKGDEY-HTQZYQBOSA-N Chorismic acid Natural products O[C@@H]1C=CC(C(O)=O)=C[C@H]1OC(=C)C(O)=O WTFXTQVDAKGDEY-HTQZYQBOSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 241001646716 Escherichia coli K-12 Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 101150037050 LE gene Proteins 0.000 description 2
- 101100269389 Mus musculus Pgm3 gene Proteins 0.000 description 2
- 108010076181 Proinsulin Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 108010078233 Thymalfasin Proteins 0.000 description 2
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000001036 exonucleolytic effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000013606 secretion vector Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 2
- 229960004231 thymalfasin Drugs 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- WBQJTPDOGLYTBE-VIFPVBQESA-N 1-nitroso-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CN(N=O)C2=C1 WBQJTPDOGLYTBE-VIFPVBQESA-N 0.000 description 1
- NSHWGYPCYVZQOD-UHFFFAOYSA-N 2-(1h-indol-2-yl)prop-2-enoic acid Chemical compound C1=CC=C2NC(C(=C)C(=O)O)=CC2=C1 NSHWGYPCYVZQOD-UHFFFAOYSA-N 0.000 description 1
- UTWSLTKGFRKQTA-QHPFDFDXSA-N 2-[[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-phosphonoamino]benzoic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)OC1N(P(O)(O)=O)C1=CC=CC=C1C(O)=O UTWSLTKGFRKQTA-QHPFDFDXSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 108700034853 E coli TRPR Proteins 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 101710149086 Nuclease S1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101800001530 Thymosin alpha Proteins 0.000 description 1
- 108050004197 Trp repressor Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 235000005550 amino acid supplement Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- CSCNMBQITNFHLH-UHFFFAOYSA-L copper;hydrogen phosphate Chemical compound [Cu+2].OP([O-])([O-])=O CSCNMBQITNFHLH-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000037048 polymerization activity Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13329680A | 1980-03-24 | 1980-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS238645B2 true CS238645B2 (en) | 1985-12-16 |
Family
ID=22457906
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS812106A CS238612B2 (en) | 1980-03-24 | 1981-03-23 | Production method of polypeptide product |
| CS816231A CS238646B2 (en) | 1980-03-24 | 1981-03-23 | Fission method of two-fibre dna at any point |
| CS816230A CS238645B2 (en) | 1980-03-24 | 1981-03-23 | Design method of plasmide capable to separate heterological gen |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS812106A CS238612B2 (en) | 1980-03-24 | 1981-03-23 | Production method of polypeptide product |
| CS816231A CS238646B2 (en) | 1980-03-24 | 1981-03-23 | Fission method of two-fibre dna at any point |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US5888808A (pl) |
| EP (3) | EP0086548B1 (pl) |
| JP (3) | JPH0724582B2 (pl) |
| KR (2) | KR830005351A (pl) |
| AR (1) | AR248050A1 (pl) |
| AT (3) | ATE52802T1 (pl) |
| AU (3) | AU542640B2 (pl) |
| BG (3) | BG46005A3 (pl) |
| BR (1) | BR8101712A (pl) |
| CA (2) | CA1198068A (pl) |
| CS (3) | CS238612B2 (pl) |
| DD (3) | DD203746A5 (pl) |
| DE (5) | DE3176205D1 (pl) |
| DK (1) | DK173085B1 (pl) |
| DZ (1) | DZ278A1 (pl) |
| ES (3) | ES500617A0 (pl) |
| FI (3) | FI810876A7 (pl) |
| FR (2) | FR2480781B1 (pl) |
| GB (1) | GB2073203B (pl) |
| GR (1) | GR74818B (pl) |
| HU (1) | HU195534B (pl) |
| IE (3) | IE51892B1 (pl) |
| IL (3) | IL62460A (pl) |
| IT (1) | IT1144324B (pl) |
| MX (1) | MX7689E (pl) |
| MY (1) | MY8500896A (pl) |
| NO (3) | NO810986L (pl) |
| NZ (3) | NZ207659A (pl) |
| OA (1) | OA06774A (pl) |
| PH (4) | PH17537A (pl) |
| PL (2) | PL147727B1 (pl) |
| PT (1) | PT72716B (pl) |
| YU (2) | YU45534B (pl) |
| ZA (1) | ZA811368B (pl) |
| ZW (1) | ZW5481A1 (pl) |
Families Citing this family (371)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1202581A (en) * | 1980-03-27 | 1986-04-01 | Saran A. Narang | Adaptor molecules for dna and their application to synthesis of gene-derived products |
| YU45104B (en) | 1980-04-03 | 1992-03-10 | Biogen Nv | Process for producing recombinant dnk molecule, capable of inducting polypeptide expression in an one-cell host |
| US4874702A (en) * | 1980-09-08 | 1989-10-17 | Biogen, Inc. | Vectors and methods for making such vectors and for expressive cloned genes |
| DK489481A (da) * | 1980-11-10 | 1982-05-11 | Searle & Co | Plasmidvektor og frmgangsmaade til fremstilling deraf |
| US5525484A (en) * | 1981-01-16 | 1996-06-11 | Genome Therapeutics Corp. | Recombinant DNA means and method for producing rennin, prorenin and pre-prorennin |
| BR8205954A (pt) * | 1981-10-14 | 1983-09-13 | Unilever Nv | Sequencia de dna,plasmidio recombinante,cultura bacteriana e microorganismos |
| JPS58110600A (ja) * | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド |
| JPS58141796A (ja) * | 1982-02-18 | 1983-08-23 | Kyowa Hakko Kogyo Co Ltd | ペプチドの製造法 |
| DE3382317D1 (de) * | 1982-03-15 | 1991-07-25 | Schering Corp | Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer. |
| US4499188A (en) * | 1982-05-05 | 1985-02-12 | Cetus Corporation | Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator |
| US4863855A (en) * | 1982-05-14 | 1989-09-05 | The Research Foundation Of State University Of New York | Novel cloning vehicles for polypeptide expression in microbial hosts |
| DE3378638D1 (de) * | 1982-10-25 | 1989-01-12 | Monsanto Co | Reca promoter dependent polypeptide production |
| IE56509B1 (en) * | 1982-11-04 | 1991-08-28 | Univ California | Methods for oncogenic detection |
| DE3247922A1 (de) * | 1982-12-24 | 1984-06-28 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten |
| US5169762A (en) * | 1983-03-03 | 1992-12-08 | Genentech, Inc. | Human nerve growth factor by recombinant technology |
| DK161152C (da) | 1983-03-03 | 1991-11-11 | Genentech Inc | Polypeptid med egenskaber som human beta-nervevaekstfaktor og fremgangsmaade til fremstilling deraf, dna-isolat omfattende en sekvens som koder for polypeptidet, replicerbar udtrykkelsesvektor for dna-sekvensen, rekombinant vaertscelle transformeret med vektoren, farmaceutisk praeparat indeholdende polypeptidet og fremg. der omfatter anvendelsen af polypeptidet til fremst. af et farmaceutisk praeparat |
| US4701416A (en) * | 1983-12-09 | 1987-10-20 | Cetus Corporation | Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV |
| US4935370A (en) * | 1983-12-23 | 1990-06-19 | Pfizer Inc. | Expression plasmids for improved production of heterologous protein in bacteria |
| WO1985003522A1 (en) * | 1984-02-08 | 1985-08-15 | Cetus Corporation | Monitoring and control systems for recombinant manipulations |
| GB8407044D0 (en) * | 1984-03-19 | 1984-04-26 | Fujisawa Pharmaceutical Co | Producing human insulin |
| US5028531A (en) * | 1984-03-19 | 1991-07-02 | Fujisawa Pharmaceutical Company, Ltd. | IGF-I fusion proteins; protection of IGF-I from degradation by host cell; and processes for the production thereof |
| US4656132A (en) | 1984-03-28 | 1987-04-07 | Cetus Corporation | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria |
| US4894334A (en) * | 1984-03-28 | 1990-01-16 | Cetus Corporation | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria |
| US5268278A (en) * | 1984-03-30 | 1993-12-07 | Istituto Farmacologico Serono S.P.A. | Genetic expression of somatostatin as hybrid polypeptide |
| US4789702A (en) * | 1984-05-18 | 1988-12-06 | Cetus Corporation | Feline leukemia virus vaccine |
| US5683688A (en) * | 1984-05-31 | 1997-11-04 | Genentech, Inc. | Unglycosylated recombinant human lymphotoxin polypeptides and compositions |
| JPS619282A (ja) * | 1984-06-22 | 1986-01-16 | Hitachi Ltd | 遺伝子組換え菌の培養方法 |
| EP0165613B1 (en) * | 1984-06-22 | 1992-01-15 | Hitachi, Ltd. | Process for controlling culture of recombinants |
| JPS6158595A (ja) * | 1984-08-28 | 1986-03-25 | ジェネックス・コーポレイション | 徴生物によるタンパク質規模生産方法 |
| US4738921A (en) * | 1984-09-27 | 1988-04-19 | Eli Lilly And Company | Derivative of the tryptophan operon for expression of fused gene products |
| US5075224A (en) * | 1984-10-19 | 1991-12-24 | Genentech, Inc. | Prepro-LHRH C-terminal peptide DNA |
| NZ213759A (en) * | 1984-10-19 | 1989-01-27 | Genentech Inc | Lhrh-ctp protein conjugates influencing prolactin fsh and lh release |
| FI90990C (fi) * | 1984-12-18 | 1994-04-25 | Boehringer Ingelheim Int | Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi |
| DE3650625T2 (de) | 1985-01-28 | 1997-10-02 | Xoma Corp | AraB-Promoter und Verfahren zur Herstellung von Polypeptiden einschliesslich Cecropinen mittels mikrobiologischer Verfahren |
| IT1234977B (it) * | 1985-03-22 | 1992-06-09 | Serono Ist Farm | Espressione in e. coli polipeptidi ibridi contenenti la sequenza del fattore di rilascio dell'ormone della crescita |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| ES8706823A1 (es) * | 1985-03-28 | 1987-06-16 | Cetus Corp | Un procedimiento para detectar la presencia o ausencia de al menos una secuencia especifica de acidos nucleicos en una muestra |
| US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| GB8509289D0 (en) * | 1985-04-11 | 1985-05-15 | Fujisawa Pharmaceutical Co | Production of somatostatin |
| DE3526995A1 (de) * | 1985-07-27 | 1987-02-05 | Hoechst Ag | Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung |
| EP0213472A1 (en) * | 1985-08-12 | 1987-03-11 | Syntex (U.S.A.) Inc. | Method for producing fusion proteins |
| EP0212532A1 (en) * | 1985-08-12 | 1987-03-04 | Syntex (U.S.A.) Inc. | Method for producing fusion proteins |
| JPH0775536B2 (ja) * | 1986-03-26 | 1995-08-16 | 猛 小林 | 遺伝子組み換え菌を用いた酵素生産装置 |
| DE3642096A1 (de) * | 1986-12-10 | 1988-06-16 | Boehringer Ingelheim Int | Pferde-(gamma)-interferon |
| US6994988B1 (en) | 1987-02-12 | 2006-02-07 | Genetech, Inc. | Methods and deoxyribonucleic acid for the preparation of tissue factor protein |
| DE68915841T2 (de) * | 1988-03-30 | 1995-02-02 | Hitachi Chemical Co Ltd | Verfahren zur Herstellung von Epidermal-Wachstumsfaktor durch genetische Transformation. |
| JPH01247098A (ja) * | 1988-03-30 | 1989-10-02 | Hitachi Ltd | ヒトの上皮細胞増殖因子の遺伝子工学的生産方法 |
| JPH01247099A (ja) * | 1988-03-30 | 1989-10-02 | Hitachi Ltd | ヒトの上皮細胞増殖因子の遺伝子工学的生産方法 |
| JPH0227993A (ja) * | 1988-07-15 | 1990-01-30 | Nippon Shinyaku Co Ltd | ｈＥＧＦの製法 |
| IL92937A0 (en) | 1989-01-31 | 1990-09-17 | Us Health | Human derived monocyte attracting protein,pharmaceutical compositions comprising it and dna encoding it |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| EP0785273A1 (en) | 1990-11-26 | 1997-07-23 | Genetics Institute, Inc. | Paired basic amino acid converting enzyme and DNA sequence encoding it |
| WO1993024635A1 (en) | 1992-06-03 | 1993-12-09 | Genentech, Inc. | Tissue plasminogen activator glycosylation variants with improved therapeutic properties |
| GB9325182D0 (en) * | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
| US6001604A (en) * | 1993-12-29 | 1999-12-14 | Bio-Technology General Corp. | Refolding of proinsulins without addition of reducing agents |
| US5629167A (en) | 1994-04-19 | 1997-05-13 | Biocine S.P.A. | Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay |
| US5708142A (en) | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
| US6951743B2 (en) | 1997-10-31 | 2005-10-04 | University Of Oklahoma Board Of Regents | Hyaluronan synthase genes and expression thereof in bacillus hosts |
| US6455304B1 (en) | 1994-07-01 | 2002-09-24 | The Board Of Regents Of The University Of Oklahoma | Hyaluronate synthase gene and uses thereof |
| US7091008B1 (en) | 1994-07-01 | 2006-08-15 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase genes and expression thereof in Bacillus hosts |
| US6015660A (en) * | 1995-01-06 | 2000-01-18 | The Regents Of The University Of California | Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases |
| US6113905A (en) * | 1995-01-06 | 2000-09-05 | The Regents Of The University Of California | Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases |
| US6077510A (en) * | 1995-01-06 | 2000-06-20 | Regents Of The University Of California | Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases |
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| EP1666591B1 (en) | 1995-06-29 | 2011-03-23 | Immunex Corporation | Cytokine that induces apoptosis |
| US6020473A (en) | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
| US7005505B1 (en) | 1995-08-25 | 2006-02-28 | Genentech, Inc. | Variants of vascular endothelial cell growth factor |
| US6998116B1 (en) | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
| US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| EP1500702A1 (en) | 1996-04-01 | 2005-01-26 | Genentech, Inc. | APO-2LI and APO-3 apoptosis polypeptides from the TNFR1 familiy |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
| US6159462A (en) * | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
| US6462176B1 (en) | 1996-09-23 | 2002-10-08 | Genentech, Inc. | Apo-3 polypeptide |
| US5990281A (en) * | 1996-09-30 | 1999-11-23 | Genentech, Inc. | Vertebrate smoothened proteins |
| US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
| CA2274987C (en) | 1996-12-23 | 2012-01-24 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily |
| WO1999021999A2 (en) | 1997-10-29 | 1999-05-06 | Genentech, Inc. | Wnt-1 inducible genes |
| WO1999021998A1 (en) | 1997-10-29 | 1999-05-06 | Genentech, Inc. | Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3 |
| EP1015669B1 (en) * | 1997-04-04 | 2010-11-17 | University Of Southern California | Electroplating method for forming a multilayer structure |
| US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| US6448035B1 (en) | 1997-04-24 | 2002-09-10 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR) |
| US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| CA2293724C (en) | 1997-06-05 | 2010-02-02 | Xiaodong Wang | Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
| EP1032661A1 (en) | 1997-06-18 | 2000-09-06 | Genentech, Inc. | Apo-2DcR |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| PT1007546E (pt) | 1997-08-27 | 2009-04-24 | Childrens Hosp & Res Ct Oak | Compostos miméticos moleculares de epítopos de meningococos do serogrupo b |
| US6610838B1 (en) | 1997-09-10 | 2003-08-26 | Symbicom Aktiebolag | P13 antigens from Borrelia |
| IL134578A0 (en) | 1997-09-18 | 2001-04-30 | Genentech Inc | DcR3 POLYPEPTIDE, A TNFR HOMOLOG |
| DE69840631D1 (de) | 1997-10-10 | 2009-04-16 | Genentech Inc | Apo-3 ligand |
| CN1322121C (zh) | 1997-10-31 | 2007-06-20 | 俄克拉何马大学董事会 | 透明质酸合酶基因及其应用 |
| CN101113436B (zh) | 1997-10-31 | 2013-02-06 | 俄克拉何马大学董事会 | 透明质酸合酶基因及其应用 |
| JP4472866B2 (ja) | 1997-11-06 | 2010-06-02 | カイロン ソチエタ ア レスポンサビリタ リミタータ | ナイセリア抗原 |
| US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
| EP2014677A1 (en) | 1997-11-21 | 2009-01-14 | Genentech, Inc. | A-33 related antigens and their pharmacological uses |
| SG152917A1 (en) | 1998-01-14 | 2009-06-29 | Chiron Srl | Neisseria meningitidis antigens |
| US6740739B1 (en) | 1998-01-15 | 2004-05-25 | Genentech, Inc. | Substitutional variants of APO-2 ligand |
| US6727079B1 (en) | 1998-02-25 | 2004-04-27 | The United States Of America As Represented By The Department Of Health And Human Services | cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product |
| EP2050762A3 (en) | 1998-03-10 | 2009-07-08 | Genentech, Inc. | Human cornichon-like protein and nucleic acids encoding it |
| ATE405651T1 (de) | 1998-03-17 | 2008-09-15 | Genentech Inc | Zu vegf und bmp1 homologe polypeptide |
| US6987023B2 (en) | 1998-04-02 | 2006-01-17 | The Board Of Regents Of The University Of Oklahoma | DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use |
| US20060188966A1 (en) | 1998-04-02 | 2006-08-24 | Deangelis Paul L | Natural, chimeric and hybrid glycosaminoglycan polymers and methods of making and using same |
| US7223571B2 (en) | 1998-04-02 | 2007-05-29 | The Board Of Regents Of The Universtiy Of Oklahoma | Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same |
| GB9808932D0 (en) | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
| DK1093517T3 (da) | 1998-05-01 | 2008-06-23 | Novartis Vaccines & Diagnostic | Neisseria-meningitidis-antigener og præparater |
| EP3112468A1 (en) | 1998-05-15 | 2017-01-04 | Genentech, Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
| EP1865061A3 (en) | 1998-05-15 | 2007-12-19 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| JP3577586B2 (ja) | 1998-05-15 | 2004-10-13 | ジェネンテック・インコーポレーテッド | Ｉｌ−１７相同的ポリペプチドとその治療用途 |
| US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
| CA2340790C (en) | 1998-08-21 | 2012-07-10 | Immunex Corporation | Human il-1 epsilon dna and polypeptides |
| US6261810B1 (en) | 1998-09-03 | 2001-07-17 | Bristol-Myers Squibb Company | Enzymatic oxidative deamination process |
| WO2000022130A2 (en) | 1998-10-15 | 2000-04-20 | Chiron Corporation | Metastatic breast and colon cancer regulated genes |
| US7094581B2 (en) | 1998-10-26 | 2006-08-22 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthases and methods of making and using same |
| EP1141331B1 (en) | 1998-12-16 | 2008-09-17 | Novartis Vaccines and Diagnostics, Inc. | HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE) |
| EP2075335A3 (en) | 1998-12-22 | 2009-09-30 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| AU778759B2 (en) | 1998-12-23 | 2004-12-16 | Genentech Inc. | IL-1 related polypeptides |
| NZ530640A (en) | 1999-04-30 | 2006-06-30 | Chiron S | Conserved neisserial antigens |
| GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| EP1953173B1 (en) | 1999-06-15 | 2009-11-18 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids endoding the same |
| US7101989B1 (en) | 1999-07-09 | 2006-09-05 | University Of North Carolina At Chapel Hill | DsrA protein and polynucleotides encoding the same |
| GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
| EP2308974A3 (en) | 1999-10-14 | 2011-08-10 | Clontech Laboratories Inc. | Anthozoa derived chromo/fluoroproteins and methods for using the same |
| AU1095001A (en) | 1999-10-20 | 2001-04-30 | Genentech Inc. | Type i cytokine receptor tccr |
| EP2275553B1 (en) | 1999-10-29 | 2015-05-13 | Novartis Vaccines and Diagnostics S.r.l. | Neisserial antigenic peptides |
| US7078382B1 (en) | 1999-11-02 | 2006-07-18 | Genentech, Inc. | Modulation of eNOS activity and therapeutic uses thereof |
| EP1231830A4 (en) | 1999-11-10 | 2005-05-11 | Univ Washington | COMPOSITIONS AND METHOD FOR MODULATING THE VEGETABLE CELL PARTITION |
| EP1250426A2 (en) | 1999-12-01 | 2002-10-23 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding same |
| NZ520171A (en) | 1999-12-20 | 2005-07-29 | Immunex Corp | Tweak receptor |
| EP1897944B1 (en) | 1999-12-23 | 2011-08-10 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| DE60017942T2 (de) | 1999-12-30 | 2006-05-18 | Genencor International, Inc., Palo Alto | Trichoderma reesei xylanase |
| WO2001051515A2 (en) | 2000-01-10 | 2001-07-19 | Chiron Corporation | Genes differentially expressed in breast cancer |
| ES2323220T3 (es) | 2000-01-13 | 2009-07-09 | Genentech, Inc. | Polipeptidos humanos stra6. |
| CA2871789C (en) | 2000-01-17 | 2017-04-04 | Novartis Vaccines And Diagnostics S.R.L. | Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins |
| US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| JP2003528071A (ja) | 2000-03-23 | 2003-09-24 | エラン ファーマスーティカルズ インコーポレイテッド | アルツハイマー病治療用組成物および方法 |
| EP2275549A1 (en) | 2000-06-23 | 2011-01-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| CA2709771A1 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| ATE302751T1 (de) | 2000-06-30 | 2005-09-15 | Elan Pharm Inc | Verbindungen zur behandlung der alzheimerischen krankheit |
| US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| DE60136281D1 (de) | 2000-08-24 | 2008-12-04 | Genentech Inc | Methode zur inhibierung von il-22 induziertem pap1 |
| EP1944317A3 (en) | 2000-09-01 | 2008-09-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6673580B2 (en) | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
| ES2330083T3 (es) | 2000-10-27 | 2009-12-04 | Novartis Vaccines And Diagnostics S.R.L. | Acidos nucleicos y proteinas de estreptococos de los grupos a y b. |
| GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| WO2002081639A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc2 and diagnostic and therapeutic uses thereof |
| AU2002305151A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
| AU2002258728A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc-3 and diagnostic and therapeutic uses thereof |
| EP2258842A1 (en) | 2001-04-16 | 2010-12-08 | Wyeth Holdings Corporation | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| EP2000148A1 (en) | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of prostate cancer |
| MXPA04000140A (es) | 2001-06-27 | 2004-06-03 | Elan Pharm Inc | Derivados de beta-hidroxiamina utiles en el tratamiento de enfermedad de alzheimer. |
| US6867189B2 (en) | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
| US20050232936A1 (en) | 2001-07-27 | 2005-10-20 | Chiron Corporation | Meningococcus adhesins nada, app and orf 40 |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| ES2386346T3 (es) | 2001-08-29 | 2012-08-17 | Genentech, Inc. | Ácidos nucleicos y polipéptidos Bv8 con actividad mitógena |
| EP2153843B1 (en) | 2001-09-18 | 2012-08-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| CN100515494C (zh) | 2001-12-12 | 2009-07-22 | 启龙有限公司 | 抗沙眼衣原体的免疫 |
| WO2003054158A2 (en) | 2001-12-19 | 2003-07-03 | The University Of Chicago | Rapidly maturing fluorescent proteins and methods for using the same |
| MXPA04006554A (es) | 2002-01-02 | 2005-03-31 | Genentech Inc | Composiciones y metodos para diagnostico y tratamiento de tumor. |
| WO2003072035A2 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7244565B2 (en) | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
| US7138512B2 (en) | 2002-04-10 | 2006-11-21 | Georgetown University | Gene SHINC-2 and diagnostic and therapeutic uses thereof |
| KR20040101502A (ko) | 2002-04-16 | 2004-12-02 | 제넨테크, 인크. | 종양의 진단 및 치료 방법 및 이를 위한 조성물 |
| CA2485695A1 (en) | 2002-05-24 | 2003-12-04 | Fred W. Wagner | Method for universal enzymatic production of bioactive peptides |
| EP1572720A4 (en) | 2002-05-24 | 2008-12-24 | Nps Allelix Corp | PROCESS FOR THE ENZYMATIC PRODUCTION OF GLP-2 (1-34) AND GLP-2 (1-33) PEPTIDES |
| EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2003103581A2 (en) | 2002-06-05 | 2003-12-18 | Genentech, Inc. | Compositions and methods for liver growth and liver protection |
| JP2005528905A (ja) | 2002-06-07 | 2005-09-29 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
| CA2489588A1 (en) | 2002-07-08 | 2004-01-15 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004024068A2 (en) | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| US20060199181A1 (en) | 2002-09-11 | 2006-09-07 | Genentch, Inc. | Compositions and methods for the treatment of immune related diseases |
| AU2003291625B2 (en) | 2002-09-16 | 2009-10-08 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP2500438A3 (en) | 2002-09-25 | 2012-11-28 | Genentech, Inc. | Novel compositions and methods for the treatment of psoriasis |
| CN1703507B (zh) | 2002-10-04 | 2010-09-29 | 弗门尼舍有限公司 | 倍半萜烯合成酶及其使用方法 |
| EP2322200A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| CA2503748A1 (en) | 2002-11-08 | 2004-05-27 | Genentech, Inc. | Compositions and methods for the treatment of natural killer cell related diseases |
| ATE466875T1 (de) | 2002-11-15 | 2010-05-15 | Novartis Vaccines & Diagnostic | Unerwartete oberflächenproteine in neisseria meningitidis |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| EP2314676A1 (en) | 2002-11-26 | 2011-04-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7632810B2 (en) | 2003-03-12 | 2009-12-15 | Genentech, Inc. | Compositions with hematopoietic and immune activity |
| EP2335725B1 (en) | 2003-04-04 | 2016-10-12 | Genentech, Inc. | High concentration antibody and protein formulations |
| GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
| EP1658303A4 (en) | 2003-04-25 | 2008-07-16 | Univ North Carolina State | LACTOBACILLUS ACIDOPHILUS NUCLEIC ACID CODING FOR CELL SURFACE PROTEIN HOMOLOGOUS |
| US7407787B2 (en) | 2003-06-23 | 2008-08-05 | North Carolina State University | Lactobacillus acidophilus nucleic acids encoding fructo-oligosaccharide utilization compounds and uses thereof |
| EP2784084B2 (en) | 2003-07-08 | 2023-10-04 | Novartis Pharma AG | Antagonist antibodies to IL-17A/F heterologous polypeptides |
| US7442785B2 (en) | 2003-07-24 | 2008-10-28 | The University Of Kentucky Research Foundation | Sesquiterpene synthase gene and protein |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| PL1842920T5 (pl) | 2003-09-23 | 2018-04-30 | University Of North Carolina At Chapel Hill | Komórki koekspresjonujące reduktazę witaminy K i białko zależne od witaminy K oraz ich zastosowanie do poprawienia wydajności wytwarzania tego białka zależnego od witaminy K |
| DE602004026897D1 (de) | 2003-10-14 | 2010-06-10 | Baxter Healthcare Sa | Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate |
| ES2472690T3 (es) | 2003-11-17 | 2014-07-02 | Genentech, Inc. | Anticuerpo contra CD22 para el tratamiento de tumores de origen hematopoy�tico |
| CA2546319A1 (en) | 2003-11-21 | 2005-07-28 | Nps Allelix Corp. | Production of glucagon like peptide 2 and analogs |
| WO2005074546A2 (en) | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| US7459289B2 (en) | 2004-03-08 | 2008-12-02 | North Carolina State University | Lactobacillus acidophilus nucleic acid sequences encoding carbohydrate utilization-related proteins and uses therefor |
| KR101222281B1 (ko) | 2004-03-29 | 2013-01-28 | 가르파마 컴퍼니 리미티드 | 신규 갈렉틴 9 개변체 단백질 및 그 용도 |
| EP1732944B1 (en) | 2004-04-07 | 2012-09-05 | The University of Chicago | Monomeric red fluorescent proteins |
| NZ582684A (en) | 2004-06-18 | 2011-05-27 | Ambrx Inc | Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker |
| JP2008507280A (ja) | 2004-07-21 | 2008-03-13 | アンブレツクス・インコーポレイテツド | 非天然コードアミノ酸を用いた生合成ポリペプチド |
| WO2007001423A2 (en) | 2004-10-21 | 2007-01-04 | Wyeth | Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens |
| CA2590590C (en) | 2004-12-22 | 2016-04-19 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| SG176509A1 (en) | 2004-12-22 | 2011-12-29 | Genentech Inc | Methods for producing soluble multi-membrane-spanning proteins |
| KR20070090023A (ko) | 2004-12-22 | 2007-09-04 | 암브룩스, 인코포레이티드 | 변형 인간 성장 호르몬 |
| CA2601574C (en) | 2005-03-15 | 2014-12-02 | University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin k-dependent proteins |
| HRP20130419T1 (en) | 2005-03-21 | 2013-06-30 | Virobay, Inc. | Alpha ketoamide compounds as cysteine protease inhibitors |
| BRPI0610609A2 (pt) | 2005-04-15 | 2010-07-06 | Univ North Carolina State | métodos e composições para modular a adesão e toleráncia ao estresse em bactérias |
| AU2006242998B2 (en) | 2005-05-04 | 2012-03-22 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
| EP3214095B1 (en) | 2005-05-12 | 2019-12-11 | ZymoGenetics, Inc. | Compositions and methods for modulating immune responses |
| US7858843B2 (en) | 2005-06-06 | 2010-12-28 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| BRPI0614695A2 (pt) | 2005-07-29 | 2011-04-12 | Targeted Growth Inc | proteção de proteìna krp mutante negativa dominante de inibição de complexo ciclina-cdk ativo por krp do tipo silvestre |
| AU2006280321A1 (en) | 2005-08-15 | 2007-02-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| EP3896076A1 (en) | 2005-08-31 | 2021-10-20 | The Regents of the University of California | Cellular libraries of peptide sequences (clips) and methods of using the same |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| DE102005048898A1 (de) | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen |
| JP2009511081A (ja) | 2005-10-18 | 2009-03-19 | ナショナル ジューイッシュ メディカル アンド リサーチ センター | 条件的に不死化された長期幹細胞およびそのような細胞を作製および使用する方法 |
| WO2007053732A2 (en) | 2005-11-01 | 2007-05-10 | Mayo Foundation For Medical Education And Research | Promoter polymorphisms of the blys gene and use in diagnostic methods |
| EP1951890A4 (en) | 2005-11-16 | 2009-06-24 | Ambrx Inc | PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS |
| EP2002714A1 (en) | 2005-11-21 | 2008-12-17 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
| US8026354B2 (en) | 2005-11-23 | 2011-09-27 | Institut Pasteur | Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| EP1973942B1 (en) | 2005-12-22 | 2011-02-09 | Genentech, Inc. | Recombinant production of heparin binding proteins |
| JP2009527227A (ja) | 2006-02-17 | 2009-07-30 | ジェネンテック・インコーポレーテッド | 遺伝子破壊、それに関連する組成物および方法 |
| WO2008036437A2 (en) | 2006-04-19 | 2008-03-27 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
| CA2650730A1 (en) | 2006-04-27 | 2007-11-08 | Pikamab, Inc. | Methods and compositions for antibody therapy |
| PT2054431E (pt) | 2006-06-09 | 2011-11-03 | Novartis Ag | Confórmeros de adesinas bacterianas |
| CA2656558A1 (en) | 2006-06-30 | 2008-01-10 | The Regents Of The University Of Michigan | Method of producing factor viii proteins by recombinant methods |
| CN104193815A (zh) | 2006-09-08 | 2014-12-10 | Ambrx公司 | 经修饰的人类血浆多肽或Fc骨架和其用途 |
| US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
| JP5519287B2 (ja) | 2006-11-02 | 2014-06-11 | ダニエル・ジェイ・カポン | 可動部を備えたハイブリッド免疫グロブリン |
| US7875431B2 (en) | 2007-02-22 | 2011-01-25 | Genentech, Inc. | Methods for detecting inflammatory bowel disease |
| KR20140012199A (ko) | 2007-03-30 | 2014-01-29 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| AU2008242748B2 (en) | 2007-04-20 | 2013-12-05 | Unikeris Limited | Stable recombinant adenosine deaminase |
| CA3090908A1 (en) | 2007-04-26 | 2008-11-06 | Aptevo Biotherapeutics Llc | Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same |
| AR067543A1 (es) | 2007-07-16 | 2009-10-14 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso |
| CN106432496B (zh) | 2007-07-16 | 2020-02-07 | 健泰科生物技术公司 | 抗cd79b抗体和免疫偶联物及使用方法 |
| WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗脂肪肝中的应用 |
| ES2629440T5 (es) | 2007-10-04 | 2020-11-20 | Zymogenetics Inc | zB7H6 miembro de la familia B7 y composiciones y métodos relacionados |
| US20090233990A1 (en) | 2007-11-01 | 2009-09-17 | Hee Cheol Cho | Generation of biological pacemaker activity |
| US8679749B2 (en) | 2007-11-01 | 2014-03-25 | The University Of Chicago | Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation |
| EP2930182A1 (en) | 2007-11-20 | 2015-10-14 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| WO2009070648A2 (en) | 2007-11-27 | 2009-06-04 | Medtronic, Inc. | Humanized anti-amyloid beta antibodies |
| US8003325B2 (en) | 2007-11-30 | 2011-08-23 | Mayo Foundation For Medical Education And Research | Polymorphisms of the BLyS gene and use in diagnostic methods |
| EP2247620B1 (en) | 2008-01-31 | 2016-05-18 | Genentech, Inc. | Anti-cd79b antibodies and immunoconjugates and methods of use |
| EP3103880A1 (en) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
| NZ587382A (en) | 2008-02-21 | 2012-01-12 | Novartis Ag | Meningococcal fhbp polypeptides |
| CN102057272B (zh) | 2008-04-09 | 2015-02-18 | 健泰科生物技术公司 | 用于免疫相关疾病的治疗的新组合物和方法 |
| AU2009246876B2 (en) | 2008-05-16 | 2015-04-02 | Htyr Acquisition Llc | Antibodies and processes for preparing the same |
| AU2009274076C1 (en) | 2008-07-23 | 2014-04-17 | Ambrx, Inc. | Modified bovine G-CSF polypeptides and their uses |
| CA2735522C (en) | 2008-08-28 | 2017-04-18 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc |
| US9121024B2 (en) | 2008-09-26 | 2015-09-01 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
| PL2342223T3 (pl) | 2008-09-26 | 2017-09-29 | Ambrx, Inc. | Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania |
| US9702877B2 (en) | 2008-10-31 | 2017-07-11 | Quest Diagnostics Investments Incorporated | BCR-ABL variants |
| AU2009319772A1 (en) | 2008-11-26 | 2010-06-03 | Centocor Research & Development, Inc. | Compositions and methods for regulating collagen and smooth muscle actin expression by SERPINE2 |
| US8716448B2 (en) | 2009-02-03 | 2014-05-06 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
| EP3178835B1 (en) | 2009-02-03 | 2019-04-10 | Amunix Pharmaceuticals, Inc. | Extended recombinant polypeptides and compositions comprising same |
| US8466260B2 (en) | 2009-04-01 | 2013-06-18 | Genentech, Inc. | Anti-FcRH5 antibodies and immunoconjugates and methods of use |
| EP2251025A1 (en) | 2009-05-12 | 2010-11-17 | Universitat Autònoma De Barcelona | Use of inclusion bodies as therapeutic agents |
| ITMI20090946A1 (it) | 2009-05-28 | 2010-11-29 | Novartis Ag | Espressione di proteine ricombinanti |
| CN102481331B (zh) | 2009-06-08 | 2017-09-22 | 阿穆尼克斯运营公司 | 葡萄糖调节多肽及其制备和使用方法 |
| CA2764105A1 (en) | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| EP2448593B1 (en) | 2009-07-03 | 2020-11-25 | Bionor Immuno AS | Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means |
| EP3017828A1 (en) | 2009-08-27 | 2016-05-11 | GlaxoSmithKline Biologicals SA | Hybrid polypeptides including meningococcal fhbp sequences |
| US9488656B2 (en) | 2009-09-30 | 2016-11-08 | Quest Diagnostics Investments Incorporated | BCR-ABL truncation mutations |
| EP2486131A1 (en) | 2009-10-06 | 2012-08-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Carbapenemase and antibacterial treatment |
| MX2012004303A (es) | 2009-10-15 | 2012-06-25 | Genentech Inc | Factores de crecimiento de fibroblasto quimericos con especificacion de receptor alterada. |
| ES2564207T3 (es) | 2009-10-22 | 2016-03-18 | F. Hoffmann-La Roche Ag | Métodos y composiciones para modular la activación con hepsina de la proteína estimuladora de macrófagos |
| WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
| WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
| WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
| WO2011051893A1 (en) | 2009-10-27 | 2011-05-05 | Novartis Ag | Modified meningococcal fhbp polypeptides |
| EP2498817A2 (en) | 2009-11-12 | 2012-09-19 | F. Hoffmann-La Roche AG | A method of promoting dendritic spine density |
| SG10201408598XA (en) | 2009-11-30 | 2015-02-27 | Genentech Inc | Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 ) |
| WO2011087810A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
| BR112012015461A2 (pt) | 2009-12-21 | 2017-01-10 | Ambrx Inc | polipeptídeos de somatotropina boviina modificados e seus usos |
| FR2954349A1 (fr) | 2009-12-22 | 2011-06-24 | Agronomique Inst Nat Rech | Sulfatase modifiant selectivement les glycosaminoglycanes |
| WO2011106297A2 (en) | 2010-02-23 | 2011-09-01 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| EP3372617B1 (en) | 2010-04-02 | 2024-07-24 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| BR112012028010A2 (pt) | 2010-05-03 | 2017-09-26 | Genentech Inc | anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero |
| WO2011146715A1 (en) | 2010-05-19 | 2011-11-24 | North Carolina State University | Compositions and methods for the delivery of therapeutic peptides |
| WO2011149461A1 (en) | 2010-05-27 | 2011-12-01 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
| JP5746761B2 (ja) | 2010-06-25 | 2015-07-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 気道感染症の処置のための方法及び医薬組成物 |
| US8853150B2 (en) | 2010-07-29 | 2014-10-07 | Eleven Biotherapeutics, Inc. | Chimeric IL-1 receptor type I antagonists |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| ES2742296T3 (es) | 2010-08-17 | 2020-02-13 | Ambrx Inc | Polipéptidos de relaxina modificados y sus usos |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| US8846890B2 (en) | 2010-08-30 | 2014-09-30 | Board Of Trustees Of Michigan State University | Microbial nanowires |
| CN102380091A (zh) | 2010-08-31 | 2012-03-21 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗病毒性肝炎中的应用 |
| WO2012036884A2 (en) | 2010-09-15 | 2012-03-22 | Aligna Technologies, Inc. | Bioproduction of aromatic chemicals from lignin-derived compounds |
| TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
| EP2441776A1 (en) | 2010-10-15 | 2012-04-18 | Leadartis, S.L. | Generation of multifunctional and multivalent polypeptide complexes with collagen XVIII trimerization domain |
| ES2701445T3 (es) | 2010-10-15 | 2019-02-22 | Leadartis S L | Generación de complejos polipeptídicos multifuncionales y multivalentes mediante el dominio de trimerización del colágeno XVIII |
| WO2012088222A2 (en) | 2010-12-21 | 2012-06-28 | The University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin k-dependent proteins |
| US8603740B2 (en) | 2010-12-29 | 2013-12-10 | Quest Diagnostics Investments Incorporated | BCR-ABL1 splice variants and uses thereof |
| WO2012095684A1 (en) | 2011-01-10 | 2012-07-19 | Inserm ( Institut National De La Sante Et De La Recherche Medicale) | Methods for the screening of substances useful for the prevention and treatment of neisseria infections |
| WO2012103240A2 (en) | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
| EP2694092B1 (en) | 2011-04-08 | 2017-01-04 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| WO2013011072A1 (en) | 2011-07-20 | 2013-01-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Carbapenemase and antibacterial treatment |
| CA2843197A1 (en) | 2011-07-29 | 2013-02-07 | Eleven Biotherapeutics, Inc. | Purified proteins |
| WO2013033456A2 (en) | 2011-09-02 | 2013-03-07 | Board Of Trustees Of Michigan State University | Microbial nanowires and methods of making and using |
| BR112014018575A2 (pt) | 2012-01-26 | 2017-07-04 | Amgen Inc | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) |
| EA201491388A1 (ru) | 2012-02-15 | 2015-01-30 | Байоджен Айдек Ма Инк. | Рекомбинантные белки фактора viii |
| DK3564260T5 (da) | 2012-02-15 | 2024-09-02 | Bioverativ Therapeutics Inc | Faktor viii-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf |
| KR102057356B1 (ko) | 2012-02-27 | 2019-12-18 | 아뮤닉스 파마슈티컬스, 인크. | Ｘｔｅｎ 콘주게이트 조성물 및 그의 제조 방법 |
| AU2013240280A1 (en) | 2012-03-27 | 2014-10-16 | Genentech, Inc. | Improved harvest operations for recombinant proteins |
| ES2648487T3 (es) | 2012-04-27 | 2018-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antagonistas de factor de crecimiento endotelial vascular y métodos para su uso |
| EP2844670B1 (en) | 2012-05-03 | 2017-12-06 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
| JP2015520179A (ja) | 2012-06-06 | 2015-07-16 | ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ | ワクチン |
| SG10201700459XA (en) | 2012-07-20 | 2017-02-27 | Taiga Biotechnologies Inc | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| WO2014026136A2 (en) | 2012-08-10 | 2014-02-13 | Cytomx Therapeutics, Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| BR112015011462A2 (pt) | 2012-11-20 | 2017-09-26 | Univ North Carolina Chapel Hill | processos e composições para proteínas fator ix modificadas |
| CA2891504A1 (en) | 2012-12-07 | 2014-06-12 | Danisco Us Inc. | Compositions and methods of use |
| US9879245B2 (en) | 2012-12-07 | 2018-01-30 | Danisco Us Inc. | Polypeptides having beta-mannanase activity and methods of use |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| SG10201707477SA (en) | 2013-03-13 | 2017-10-30 | Eleven Biotherapeutics Inc | Chimeric cytokine formulations for ocular delivery |
| US10160793B2 (en) | 2013-03-15 | 2018-12-25 | Genentech, Inc. | Methods of treating inflammatory bowel disease using IL-22 Fc fusion proteins |
| DK2968495T3 (da) | 2013-03-15 | 2019-10-14 | Daniel J Capon | Hybrid immunoglobulin indeholdende en ikke-peptid-bro |
| WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
| WO2015023891A2 (en) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Factor viii-xten fusions and uses thereof |
| US10767156B2 (en) | 2013-10-24 | 2020-09-08 | Yeda Research And Development Co., Ltd. | Polynucleotides encoding BREX system polypeptides and methods of using same |
| US20160250298A1 (en) | 2013-11-01 | 2016-09-01 | Spherium Biomed S.L. | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents |
| CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
| WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
| AU2015229186B2 (en) | 2014-03-14 | 2021-01-28 | Biomolecular Holdings Llc | Hybrid immunoglobulin containing non-peptidyl linkage |
| WO2016005508A1 (en) | 2014-07-11 | 2016-01-14 | Bionor Immuno As | Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids) |
| WO2016054168A1 (en) | 2014-09-30 | 2016-04-07 | Danisco Us Inc | Compositions comprising beta mannanase and methods of use |
| EP3201332A1 (en) | 2014-09-30 | 2017-08-09 | Danisco US Inc. | Compositions comprising beta-mannanase and methods of use |
| US20170211054A1 (en) | 2014-09-30 | 2017-07-27 | Dansico Us Inc. | Compositions comprising beta mannanase and methods of use |
| US20170218351A1 (en) | 2014-09-30 | 2017-08-03 | Danisco Us Inc. | Compositions comprising beta-mannanase and methods of use |
| EP3201334A1 (en) | 2014-09-30 | 2017-08-09 | Danisco US Inc. | Compositions comprising beta-mannanase and methods of use |
| CN107108710B (zh) | 2014-10-24 | 2022-02-15 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| US20180002683A1 (en) | 2014-12-18 | 2018-01-04 | Danisco Us Inc. | Engineered multifunctional enzymes and methods of use |
| EP3234119A1 (en) | 2014-12-18 | 2017-10-25 | Danisco US Inc. | Engineered multifunctional enzymes and methods of use |
| MX388739B (es) | 2015-02-06 | 2025-03-20 | Univ North Carolina Chapel Hill | Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso. |
| US10113193B2 (en) | 2015-03-31 | 2018-10-30 | Novimmune Sa | Method for optimizing the assembly and production of hetero-multimeric protein complexes |
| CA2984991A1 (en) | 2015-05-04 | 2016-11-10 | Bionor Immuno As | Dosage regimen for hiv vaccine |
| MX2018001497A (es) | 2015-08-03 | 2018-05-15 | Bioverativ Therapeutics Inc | Proteinas de fusion de factor ix y metodos para producirlas y usarlas. |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| EP3436610A1 (en) | 2016-03-29 | 2019-02-06 | Geltor, Inc. | Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1 |
| CN109328069B (zh) | 2016-04-15 | 2023-09-01 | 亿一生物医药开发(上海)有限公司 | Il-22在治疗坏死性小肠结肠炎中的用途 |
| US10590426B2 (en) | 2016-08-22 | 2020-03-17 | Board Of Trustees Of Michigan State University | Genetic control of cell size |
| CN113786476A (zh) | 2016-12-02 | 2021-12-14 | 泰加生物工艺学公司 | 纳米颗粒调配物 |
| EP4295840A3 (en) | 2016-12-06 | 2024-03-13 | DSM Nutritional Products, LLC | Glycan polymers and related methods thereof |
| IL250479A0 (en) | 2017-02-06 | 2017-03-30 | Sorek Rotem | Genetically engineered cells expressing a disarm system that confers resistance to phages and methods for their production |
| KR102670432B1 (ko) | 2017-02-08 | 2024-05-28 | 브리스톨-마이어스 스큅 컴퍼니 | 약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도 |
| WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
| JP6731114B2 (ja) | 2017-08-03 | 2020-07-29 | タイガ バイオテクノロジーズ，インク． | メラノーマの処置のための方法および組成物 |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| US11180541B2 (en) | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
| HRP20221448T1 (hr) | 2018-01-26 | 2023-01-20 | F. Hoffmann - La Roche Ag | Il-22 fc pripravci i postupci njihove primjene |
| MX2020007018A (es) | 2018-01-26 | 2020-09-07 | Genentech Inc | Proteinas de fusion fc il-22 y metodos de uso. |
| MX2020008502A (es) | 2018-02-21 | 2020-09-25 | Genentech Inc | Dosis para el tratamiento con proteinas de fusion il-22 fc. |
| IL258467A (en) | 2018-03-29 | 2018-07-04 | Ilana Kolodkin Gal | Methods of disrupting a biofilm and/or preventing formation of same |
| AU2019253462B2 (en) | 2018-04-09 | 2025-04-24 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
| MA52630B1 (fr) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc. | Procédés de traitement de l'hémophilie a |
| JP7557377B2 (ja) | 2018-06-06 | 2024-09-27 | レアダルティス、ソシエダッド リミターダ | 三量体ポリペプチド複合体およびその使用 |
| JP7441826B2 (ja) | 2018-09-11 | 2024-03-01 | アンブルックス，インコーポレイテッド | インターロイキン－２ポリペプチド抱合物およびその使用 |
| EP3946611A2 (en) | 2019-03-31 | 2022-02-09 | Yeda Research and Development Co. Ltd | Anti-viral and anti-tumoral compounds |
| WO2020210231A1 (en) | 2019-04-08 | 2020-10-15 | Taiga Biotechnologies, Inc. | Compositions and methods for the cry opreservation of immune cells |
| KR20210151930A (ko) | 2019-04-12 | 2021-12-14 | 젤터, 인코포레이티드 | 재조합 엘라스틴 및 이의 제조 |
| EP3969041A4 (en) | 2019-05-14 | 2023-05-10 | Taiga Biotechnologies, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION |
| KR102134418B1 (ko) * | 2019-06-17 | 2020-07-16 | 씨제이제일제당 주식회사 | L-타이로신을 생산하는 미생물 및 이를 이용한 l-타이로신 생산 방법 |
| US20210070811A1 (en) | 2019-09-05 | 2021-03-11 | Board Of Trustees Of Michigan State University | Method for protein nanowire synthesis and tunable control of nanowire length |
| CN115243726B (zh) | 2020-03-11 | 2025-07-15 | 北京泰德制药股份有限公司 | 白介素-2多肽偶联物及其使用方法 |
| WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
| EP4228656A4 (en) | 2020-08-18 | 2024-09-04 | Yeda Research and Development Co. Ltd | ANTI-VIRAL AND ANTI-TUMOR COMPOUNDS |
| US12448633B2 (en) | 2021-08-06 | 2025-10-21 | The Board Of Trustees Of The University Of Alabama | Bacterial N-demthylases as biocatalysts for the production of methylxanthines |
| IL288680A (en) | 2021-12-05 | 2023-07-01 | Yeda Res & Dev | Genetically modified phages and their use |
| EP4638773A1 (en) | 2022-12-23 | 2025-10-29 | Thermo Fisher Scientific Baltics Uab | Closed system for expressing recombinant proteins using e. coli and methods for producing clarified cell cultures thereof |
| CN120882737A (zh) | 2023-02-23 | 2025-10-31 | 微肽技术有限公司 | 控制植物病原体的抗真菌肽 |
| WO2025215636A1 (en) | 2024-04-08 | 2025-10-16 | Yeda Research And Development Co. Ltd. | Anti-defense system polypeptides and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4237224A (en) * | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| US4366246A (en) * | 1977-11-08 | 1982-12-28 | Genentech, Inc. | Method for microbial polypeptide expression |
| MW3378A1 (en) * | 1977-11-08 | 1980-03-12 | Genentech Inc | Method and means for microbial polypeptide expression;synthetic dna and process therefor |
| US4631257A (en) | 1978-12-26 | 1986-12-23 | Cetus Corporation | Stable high copy number plasmids |
| FI793884A7 (fi) * | 1978-12-26 | 1981-01-01 | Cetus Corp | Vakaita runsaasti jäljentyviä plasmideja. |
| US4332892A (en) | 1979-01-15 | 1982-06-01 | President And Fellows Of Harvard College | Protein synthesis |
| AU542264B2 (en) | 1979-06-01 | 1985-02-14 | G.D. Searle & Co. | Plasmid vectors |
| US4342832A (en) * | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
| DK33181A (da) * | 1980-02-06 | 1981-08-07 | Searle & Co | Fremgangsmaade til fremstilling af et interferonlignende protein |
| GB2068970B (en) * | 1980-02-06 | 1983-06-22 | Searle & Co | Recombinant dna technique for the preparation of a protein resembling human interferon |
| CH651308A5 (de) * | 1980-07-01 | 1985-09-13 | Hoffmann La Roche | Interferone und deren herstellung. |
| NZ198445A (en) * | 1980-09-25 | 1984-05-31 | Genentech Inc | Production of human fibroblast interferon by recombinant dna technology |
| JPS5780398A (en) * | 1980-11-05 | 1982-05-19 | Sanraku Inc | Plasmid produced by genetic manipulation, coliform bacillus having the same and preparation of tryptophan with said bacillus |
| DK489481A (da) * | 1980-11-10 | 1982-05-11 | Searle & Co | Plasmidvektor og frmgangsmaade til fremstilling deraf |
| US5145782A (en) * | 1980-12-08 | 1992-09-08 | The Regents Of The University Of California | DNA expression vector suitable for direct expression of a foreign gene |
| DE3175357D1 (en) * | 1980-12-12 | 1986-10-23 | Unilever Nv | Dna sequences encoding various allelic forms of mature thaumatin, recombinant plasmids comprising said dna's and a process for their preparation, bacterial cultures comprising said recombinant plasmids, and method for producing mature thaumatin |
-
1981
- 1981-03-02 ZA ZA00811368A patent/ZA811368B/xx unknown
- 1981-03-03 BG BG078443A patent/BG46005A3/xx unknown
- 1981-03-13 ZW ZW54/81A patent/ZW5481A1/xx unknown
- 1981-03-20 CA CA000373565A patent/CA1198068A/en not_active Expired
- 1981-03-20 FI FI810876A patent/FI810876A7/fi not_active Application Discontinuation
- 1981-03-20 FI FI853488A patent/FI853488L/fi not_active Application Discontinuation
- 1981-03-20 GR GR64454A patent/GR74818B/el unknown
- 1981-03-23 IE IE636/81A patent/IE51892B1/en not_active IP Right Cessation
- 1981-03-23 HU HU81732A patent/HU195534B/hu unknown
- 1981-03-23 EP EP83200301A patent/EP0086548B1/en not_active Expired
- 1981-03-23 IE IE657/86A patent/IE51894B1/en not_active IP Right Cessation
- 1981-03-23 DE DE8383200301T patent/DE3176205D1/de not_active Expired
- 1981-03-23 IT IT67406/81A patent/IT1144324B/it active
- 1981-03-23 EP EP85100548A patent/EP0154133B1/en not_active Expired - Lifetime
- 1981-03-23 PH PH25398A patent/PH17537A/en unknown
- 1981-03-23 BG BG078444A patent/BG45220A3/xx unknown
- 1981-03-23 NZ NZ207659A patent/NZ207659A/en unknown
- 1981-03-23 AU AU68636/81A patent/AU542640B2/en not_active Expired
- 1981-03-23 DE DE8181301227T patent/DE3176737D1/de not_active Expired
- 1981-03-23 OA OA57360A patent/OA06774A/xx unknown
- 1981-03-23 FR FR8105732A patent/FR2480781B1/fr not_active Expired
- 1981-03-23 KR KR1019810000949A patent/KR830005351A/ko not_active Ceased
- 1981-03-23 NZ NZ196584A patent/NZ196584A/en unknown
- 1981-03-23 BG BG051341A patent/BG42526A3/xx unknown
- 1981-03-23 DD DD81243408A patent/DD203746A5/de unknown
- 1981-03-23 AT AT85100548T patent/ATE52802T1/de not_active IP Right Cessation
- 1981-03-23 ES ES500617A patent/ES500617A0/es active Granted
- 1981-03-23 BR BR8101712A patent/BR8101712A/pt not_active IP Right Cessation
- 1981-03-23 AT AT83200301T patent/ATE27306T1/de not_active IP Right Cessation
- 1981-03-23 CS CS812106A patent/CS238612B2/cs unknown
- 1981-03-23 DK DK198101299A patent/DK173085B1/da active
- 1981-03-23 DE DE19813111405 patent/DE3111405A1/de active Granted
- 1981-03-23 AR AR81284705A patent/AR248050A1/es active
- 1981-03-23 NZ NZ207660A patent/NZ207660A/en unknown
- 1981-03-23 YU YU756/81A patent/YU45534B/xx unknown
- 1981-03-23 EP EP81301227A patent/EP0036776B1/en not_active Expired
- 1981-03-23 JP JP56040529A patent/JPH0724582B2/ja not_active Expired - Lifetime
- 1981-03-23 IL IL62460A patent/IL62460A/xx not_active IP Right Cessation
- 1981-03-23 PT PT72716A patent/PT72716B/pt unknown
- 1981-03-23 IL IL71885A patent/IL71885A/xx not_active IP Right Cessation
- 1981-03-23 DE DE3153606A patent/DE3153606C2/de not_active Expired - Lifetime
- 1981-03-23 IE IE656/86A patent/IE51893B1/en not_active IP Right Cessation
- 1981-03-23 CS CS816231A patent/CS238646B2/cs unknown
- 1981-03-23 DE DE8585100548T patent/DE3177179D1/de not_active Expired - Lifetime
- 1981-03-23 AT AT81301227T patent/ATE34183T1/de active
- 1981-03-23 NO NO810986A patent/NO810986L/no unknown
- 1981-03-23 GB GB8108986A patent/GB2073203B/en not_active Expired
- 1981-03-23 DD DD81228534A patent/DD159435A5/de unknown
- 1981-03-23 DD DD81243409A patent/DD204494A5/de unknown
- 1981-03-23 CS CS816230A patent/CS238645B2/cs unknown
- 1981-03-24 PL PL1981252630A patent/PL147727B1/pl unknown
- 1981-03-24 DZ DZ816135A patent/DZ278A1/fr active
- 1981-03-24 MX MX81101935U patent/MX7689E/es unknown
- 1981-03-24 PL PL81230296A patent/PL162227B1/pl unknown
-
1982
- 1982-02-26 ES ES509935A patent/ES509935A0/es active Granted
- 1982-02-26 ES ES509936A patent/ES8305042A1/es not_active Expired
- 1982-11-12 PH PH28133A patent/PH18915A/en unknown
- 1982-11-12 PH PH28135A patent/PH20736A/en unknown
- 1982-11-12 PH PH28134A patent/PH20110A/en unknown
-
1984
- 1984-02-14 YU YU00260/84A patent/YU26084A/xx unknown
- 1984-05-21 IL IL71885A patent/IL71885A0/xx unknown
- 1984-06-27 AU AU29963/84A patent/AU585832B2/en not_active Expired
- 1984-06-27 AU AU29964/84A patent/AU580959B2/en not_active Expired
- 1984-09-18 NO NO84843718A patent/NO161572C/no not_active IP Right Cessation
- 1984-09-18 NO NO84843719A patent/NO165644C/no not_active IP Right Cessation
- 1984-12-19 FR FR8419450A patent/FR2555199B1/fr not_active Expired
-
1985
- 1985-05-21 CA CA000482003A patent/CA1213539A/en not_active Expired
- 1985-09-12 FI FI853489A patent/FI72344C/fi not_active IP Right Cessation
- 1985-12-30 MY MY896/85A patent/MY8500896A/xx unknown
-
1986
- 1986-03-29 KR KR1019860002404A patent/KR860001230B1/ko not_active Expired
-
1992
- 1992-10-13 JP JP4274172A patent/JPH0734747B2/ja not_active Expired - Lifetime
- 1992-10-13 JP JP4274165A patent/JPH0673469B2/ja not_active Expired - Lifetime
-
1993
- 1993-04-29 US US08/055,960 patent/US5888808A/en not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/482,321 patent/US6333174B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CS238645B2 (en) | Design method of plasmide capable to separate heterological gen | |
| EP0075444B1 (en) | Methods and products for facile microbial expression of dna sequences | |
| PL149278B1 (en) | Method of constructing a replicating vector for cloning | |
| US4663283A (en) | Method of altering double-stranded DNA | |
| EP0067540B1 (en) | Microbial gene promoter/operators | |
| JPH0659218B2 (ja) | Ｄｎａ導入ベクタ− | |
| HU202585B (en) | Process for protecting e. coli bacterium from natural bacteriofag | |
| HU197937B (en) | Process for producing new cloning carriers usable for the expression of polypeptides in microbiological host cells | |
| EP0159123B1 (en) | Vectors for expressing bovine growth hormone derivatives | |
| EP0040466B1 (en) | Adaptor molecules for dna and their application to synthesis of gene-derived products | |
| GB2104901A (en) | Expression vectors | |
| JPS61224991A (ja) | 専門化リボソームおよびその使用方法 |